Minimally-sized DNA threads for TRNA therapy
Minimally-sized DNA threads for tRNA therapy address delivery and immune response issues in nucleic acid-based therapeutics by facilitating nuclear entry and reducing immunogenicity, enhancing the therapeutic efficacy and safety of tRNA delivery.
Patent Information
- Application Number
- PCT/US2024/020795
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-20
- Filing Date
- 2024-03-20
- Publication Date
- 2024-11-28
AI Technical Summary
Current nucleic acid-based therapeutics face challenges in delivering genetic material to the nucleus of cells and often trigger undesired immune responses, limiting their effectiveness and safety, especially upon re-administration.
The development of minimally-sized DNA threads, referred to as short linear DNA (slDNA), which are designed to encode transfer RNA (tRNA) and are engineered to be less than 475 base pairs in length, facilitating nuclear entry and reducing immunogenicity, allowing for active expression of encoded tRNAs and improved therapeutic delivery.
These DNA threads enable efficient nuclear entry and reduced immune responses, potentially leading to improved safety, efficacy, and cost profiles for tRNA therapeutics, with the ability to treat various medical conditions through systemic or local administration.
Smart Images

Figure US2024020795_28112024_PF_FP_ABST
Abstract
Description
[0001]MINIMALLY-SIZED DNA THREADS FOR TRNA THERAPY RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119 of United States provisional application 63 / 491,274, filed March 20, 2023, the entire contents of which is incorporated herein by reference. BACKGROUND DNA molecules carry genetic information in the form of the sequence of the nucleotide bases that make up the DNA polymer. Only four nucleotide bases are utilized in DNA: adenine, guanine, cytosine, and thymine. This information, in the form of codons of three contiguous bases is transcribed into messenger RNA (mRNA), and then translated by transfer RNA (tRNA) and ribosomes to form proteins. Four nucleotide bases are utilized in RNA: adenine, guanine, cytosine, and uracil. The genetic code is the relation between a triplet codon and a particular amino acid. Sixty-four possible codon triplets form the genetic code, where three stop (also called “terminating” or “nonsense”) codons provide a signal to the translation machinery (cellular ribosomes) to stop protein production at the particular codon. The other sixty-one codon triplets (also called “sense codons”) correspond to one of the 20 standard amino acids. SUMMARY OF THE INVENTION One of the challenges in nucleic acid-based therapeutics is designing a nucleic acid construct that enhances or enables therapeutic delivery to the targeted intracellular location. For example, current nucleic acid-based therapeutics, such as some non-viral technologies suitable for clinical application, facilitate entry into a cell’s cytoplasm. However, further transport into the nucleus may be hindered. In addition, another challenge of nucleic acid-based therapeutics is undesired immune responses. Such immune responses can diminish effectivess of a therapeutic, and undesired immune responses can be even more pronounced and / or problematic in the readministration context. The present disclosure, in some aspects, provides compact designs of tRNA-encoding DNA constructs in the form of a small “DNA thread”, which are also referred to herein as short linear DNA (slDNA). In some embodiments of any one of the compositions or methods provided herein, the DNA threads described herein, facilitates entry into the nucleus, e.g. through nuclear pores. In some embodiments of any one of the compositions or methods provided herein, the DNA threads described herein are less or non-immunogenic. In some embodiments of any one of the compositions or methods provided herein, delivery of the DNA threads described herein into a cell results in active expression of the encoded tRNAs. These DNA threads are applicable to numerous possible medicinal applications (therapeutic or prophylactic) when administered to a patient or administered to cells ex vivo and reintroduced into a patient. In some embodiments of any one of the compositions or methods provided herein, delivery of the DNA threads described herein to the nucleus of cells through passive nuclear entry can lead to, e.g., reduced effective dose, improved safety and cost profile, and / or improved efficacy of tRNA therapeutics. The compositions and methods provided herein may be used with or without a carrier in treatment applications. In some aspects, the present disclosure provides a DNA thread comprising a nucleotide sequence encoding a transfer RNA (tRNA). In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 475 base pairs (bps) in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 400 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 350 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 300 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 250 bp in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 200 bp in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 130 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 135 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 140 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 145 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 150 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 155 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 160 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 170 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 175 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 180 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 185 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 190 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 195 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is at least 200 bps in length. In some embodiments of any one of the compositions or methods provided herein, the tRNA is an engineered tRNA. In some embodiments of any one of the compositions or methods provided herein, the engineered tRNA is anti-codon edited-tRNA. In some embodiments of any one of the compositions or methods provided herein, the sequence encoding the at least one tRNA comprises any one of the sequences encoding a tRNA provided herein, such as any one of the sequences of Table 1 or Table 6. In some embodiments of any one of the compositions or methods provided herein, the DNA thread further comprises a promoter or a leader sequence. In some embodiments of any one of the compositions or methods provided herein, the promoter or the leader sequence is located at the 5’ end of the DNA thread. In some embodiments of any one of the compositions or methods provided herein, the promoter or the leader sequence is operably linked to the nucleotide sequence encoding the tRNA. In some embodiments of any one of the compositions or methods provided herein, the promoter or leader sequence comprises any one of the sequences encoding a promoter or leader provided herein, such as any one of the sequences of Table 2 or Table 6. In some embodiments of any one of the compositions or methods provided herein, the DNA thread further comprises a tail or trailer sequence. In some embodiments of any one of the compositions or methods provided herein, the tail or trailer sequence is located at the 3’ end of the DNA thread. In some embodiments of any one of the compositions or methods provided herein, the tail or trailer sequence comprises any one of the sequences encoding a tail or trailer provided herein, such as any one of the sequences of Table 3 or Table 6. In some embodiments of any one of the compositions or methods provided herein, the nucleotide sequence further encodes a spacer sequence. In some embodiments of any one of the compositions or methods provided herein, the spacer sequence comprises any one of the sequences encoding a spacer provided herein, such as any one of the sequences of Table 4. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is open on both ends. In some embodiments of any one of the compositions or methods provided herein, the DNA thread has one closed end. In some embodiments of any one of the compositions or methods provided herein, the DNA thread has two closed ends. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is capable of passive nuclear entry and / or has enhanced nuclear entry. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is devoid of bacterial or viral elements. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less or non-immunogenic. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is formulated with a carrier. In some embodiments of any one of the compositions or methods provided herein, the carrier is a synthetic carrier. In some embodiments of any one of the compositions or methods provided herein, the synthetic carrier comprises a lipid nanoparticle (LNP), a liposome, a polymeric nanoparticle (NP), a polymersome, an exosome, a polymer / lipid based nanocarrier, or a protein-based nanocarrier. In some aspects, the DNA thread is formulated with a pharmaceutically acceptable carrier. In some aspects, the present disclosure provides a method of delivering the DNA thread to a cell. In some embodiments of any one of the methods provided herein, the method comprises contacting the cell with the DNA thread. In some embodiments of any one of the methods provided herein, the DNA thread is delivered into the nucleus of the cell. In some embodiments of any one of the methods provided herein, the DNA thread is delivered to the nucleus of the cell through passive nuclear entry. In some aspects, the present disclosure provides a method of treating a subject in need thereof, comprising administering the DNA thread to the subject in an amount effective to treat the subject. In some embodiments of any one of the methods provided herein, the amount effective to treat the subject is a reduced effective dose. In some embodiments of any one of the methods provided herein, the administration of the DNA thread is directly into the subject. In some embodiments of any one of the methods provided herein, the administration of the DNA thread is systemic or local administration. In some embodiments of any one of the methods provided herein, the DNA thread is administered ex vivo to cells harvested from the subject. In some embodiments of any one of the methods provided herein, the harvested cells are reintroduced into the subject. In some embodiments of any one of the methods provided herein, the subject is a human. In one aspect, the DNA thread comprises any one of the sequences provided herein. BRIEF DESCRIPTION OF THE DRAWINGS The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented in this disclosure. The accompanying drawings are not intended to be drawn to scale. The drawings are illustrative only and are not required for enablement of the disclosure. For purposes of clarity, not every component may be labeled in every drawing. In the drawings: Figure 1 provides a table of the genetic code. Figure 2 shows the general four-arm structure of tRNAs comprising a T-arm, a D- arm, an anticodon arm, and an acceptor stem (or arm). These regions may also be referred to as ‘loops’ throughout. Figure 3 shows exemplary DNA threads where the DNA is open on both ends, has one closed end, or has two closed ends. Figures 4A-4B show premature termination codon (PCT) suppression of ArgTGA tRNA expressed from open-ended small linear DNAs (slDNAs). Figure 4A is a schematic of the experimental procedure used to evaluate open-ended slDNA constructs in HEK293T cells. Figure 4B shows nanoluciferase activity of 23 exemplary slDNA constructs. Positive control was an ArgTGA-expressing nanoplasmid; negative control was an slDNA expressing a native tRNA. Figures 5A-5B show cGAS activation of ArgTGA tRNA expressed from open-ended slDNAs. Figure 5A is a schematic of the experimental procedure used to evaluate slDNA constructs in HeLa cells. Figure 5B shows the concentration of cellular cGAMP, as measured by ELISA. Positive control was an ArgTGA-expressing nanoplasmid; negative control was an slDNA expressing a native tRNA. Figures 6A-6E show immune stimulation of an slDNA construct in in vitro human PBMCs. Figure 6A is a schematic of the experimental procedure used to evaluate the immune stimulation of a slDNA construct relative to an ArgTGA-expressing nanoplasmid (npDNA). PBMC = peripheral blood mononuclear cells; MΦ = macrophages; NK = natural killer cells; DC = dendritic cells. Levels of cytokine induction were observed for INF-α (Figure 6B), TNF-α (Figure 6C), IP-10 (Figure 6D), and MCP-1 (Figure 6E). Figures 7A-7E show cytokine release in mice by a slDNA construct. Figure 7A is a schematic of the experimental procedure used to evaluate cytokine release in C57BL / 6 WT mice. Levels of cytokine induction were observed for IL-6 (Figure 7B), TNF-α (Figure 7C), INF-α (Figure 7D), and INF-γ (Figure 7E). Figures 8A-8B show PTC suppression of ArgTGA tRNA expressed from an exemplary closed-ended slDNA. Figure 8A is a schematic of the experimental procedure used to evaluate a closed-ended slDNA construct (e.g., 474 bps) in HEK293T cells. Figure 8B shows nanoluciferase activity of two batches of the closed-ended slDNA at 0.02 μg / mL, 0.07 μg / mL, 0.2 μg / mL, 0.7 μg / mL, and 2 μg / mL as compared to PBS, an Arg-TGA-expressing nanoplasmid, or a closed-ended slDNA expressing a native tRNA (thread control). Figures 9A-9C show PTC expression of GlnTAA tRNA expressed from open-ended slDNA. Figure 9A is a schematic of the experimental procedure used to evaluate an open-ended slDNA construct (e.g., 474 bps) in mCherry-STOP(TAA)-EGFP cells. Figure 9B shows eGFP expression in mCherry-STOP(TAA)-EGFP cells after administration of the open-ended slDNA. Figure 9C shows a histogram of EGFP expression. Figures 10A-10D show PTC suppression in vivo in mdx mice that have a GlnTAA PTC in their dystrophin gene. Figure 10A is a schematic of the experimental procedure used to evaluate in vivo PTC suppression. Figure 10B shows gel electrophoresis results of dystrophin restoration 7 days after administration of an open-ended slDNA construct (e.g., 474 bps) expressing a GlnTAA tRNA. Figure 10C shows normalized dystrophin expression of three mice 7 days after administration of the slDNA construct. Figure 10D shows the percent relative to wild-type expression of dystrophin restored 7 days after administration of PBS or the slDNA construct. Figures 11A-11C show exemplary sequences. For each sequence, the promoter is in bold, the tRNA is highlighted in gray, the tail is underlined, and the DTS sequence is italicized. Figure 12 shows results from a PTC-nluc rescue activity assay of 5’ extended fragments with various lengths. Figure 13 shows results from a PTC-nluc rescue activity assay of 3’ extended fragments with various lengths. Figure 14 shows results from a PTC-nluc rescue activity assay of both-end extended fragments with various lengths. Figure 15 summarizes the results from PTC-nluc rescue activity assays of 3 panels of fragments at 500 ng / mL dose. DETAILED DESCRIPTION Transfer RNAs (tRNAs) are decoders of DNA and RNA “blueprints.” DNA transcription results in messenger RNAs (mRNAs) that encode primary amino acid structures that may be modified post-transcriptionally and that, upon interaction with ribosomes and tRNAs, eventually become folded or unfolded proteins. Once an mRNA engages with a ribosome, tRNAs deliver amino acids to the ribosome and form a chain of amino acids based on the code of the mRNA (Figure 1). Transfer RNA are decoders of DNA and RNA “blueprints” and help to make the proteins that form the structure of cells and tissues. tRNAs have a general four-arm structure comprising a T-arm, a D-arm, an anticodon arm, and an acceptor stem or arm (Figure 2). The T-arm is made up of a “T-stem” and a “TΨC loop.” Any one of the tRNAs provided herein can comprise this four-arm structure. The tRNAs are approximately 100 nucleotides in length, in some embodiments, and can be readily introduced into cells. The present disclosure, in some aspects, provides methods and compositions that can improve the delivery and / or nuclear entry of constructs encoding tRNAs. DNA constructs encoding tRNAs that are not able to be effectively delivered to the cell of interest and / or into the nucleus (e.g., cross the nuclear pore complex (NPC) channels) may provide limited therapeutic benefits. The DNA threads described herein may be effectively delivered into the nucleus for efficient tRNA expression. NPCs are the gateways connecting the nucleoplasm and cytoplasm. NPCs are bilateral pathways that selectively control the passage of macromolecules into and out of the nucleus. Molecules smaller than 40 kDa diffuse through the NPC passively while larger molecules require facilitated transport. Without wishing to be bound by any theory, 200–300 bp is commonly reported as the maximal length of linear DNA that can cross the NPC relatively freely. The construction of a DNA-based format for encoding tRNA at approximately 200-300 bp or less, may provide for free transport of the DNA into the cell nucleus (e.g., transport largely independent of helper molecules or transporter molecules). Facilitation of transport through the NPC by cellular factors could be beneficial for some therapeutic tRNAs, such as larger tRNAs or nucleic acids that encode the tRNAs. The present disclosure, in some aspects, provides methods and compositions that can be less or non-immunogenic. Commonly, undesired immune responses can reduce the effectiveness of therapeutics. Undesired immune responses can also be problematic for therapeutics that need to be readministered as part of a treatment of a subject. Accordingly, provided herein, in some aspects, are DNA threads that comprise a nucleotide sequence encoding a transfer RNA (tRNA). The DNA threads may have any one or combination of beneficial features provided herien. The term “DNA thread”, as used herein, refers to small DNA fragments that are largely or completely free of non-essential prokaryotic elements. In some embodiments of any one of the compositions or methods provided herein, DNA threads of the present disclosure are less than ~ 200-300 base pairs in length. In some embodiments of any one of the compositions or methods provided herein, DNA threads of the present disclosure are less than 475, 450, 425, 400, 375, 350, 325, 300 or 275 base pairs in length. In some embodiments of any one of the compositions or methods provided herein, DNA threads of the present disclosure are less than 270 base pairs in length. In an embodiment of any one of the compositions or methods provided herein, the DNA thread is less than 265 bps, less than 260 bps, less than 255 bps, less than 250 bps, less than 245 bps, less than 240 bps, less than 235 bps, less than 230 bps, less than 225 bps, less than 220 bps, less than 215 bps, less than 210 bps, less than 205 bps, less than 200 bps, less than 195 bps, less than 190 bps, less than 185 bps, less than 180 bps, less than 175 bps, less than 170 bps, less than 165 bps, less than 160 bps, less than 155 bps, or less than 150 bps, less than 145 bps, or less than 140 bps in length. In any one of the foregoing embodiments, the DNA thread is greater than 100 bps, greater than 105 bps, greater than 110 bps, greater than 115 bps, greater than 120 bps, greater than 125 bps, greater 130 bps, greater than 135 bps, greater than 140 bps, greater than 145 bps, greater than 150 bps, greater than 155 bps, greater than 160 bps, greater than 165 bps, greater than 170 bps, greater than 175 bps, greater than 180 bps, greater than 185 bps, greater than 190 bps, greater than 195 bps, or greater than 200 bps in length. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 100 bps, less than 400 bps but greater than 100 bps, less than 350 bps but greater than 100 bps, less than 300 bps but greater than 100 bps, less than 275 bps but greater than 100 bps, less than 250 bps but greater than 100 bps, less than 225 bps but greater than 100 bps, less than 200 bps but greater than 100 bps, less than 195 bps but greater than 100 bps, less than 190 bps but greater than 100 bps, less than 185 bps but greater than 100 bps, less than 180 bps but greater than 100 bps, less than 175 bps but greater than 100 bps, less than 170 bps but greater than 100 bps, less than 165 bps but greater than 100 bps, less than 160 bps but greater than 100 bps, less than 155 bps but greater than 100 bps, less than 150 bps but greater than 100 bps, less than 145 bps but greater than 100 bps, or less than 140 bps but greater than 100 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 110 bps, less than 400 bps but greater than 110 bps, less than 350 bps but greater than 110 bps, less than 300 bps but greater than 110 bps, less than 275 bps but greater than 110 bps, less than 250 bps but greater than 110 bps, less than 225 bps but greater than 110 bps, less than 200 bps but greater than 110 bps, less than 195 bps but greater than 110 bps, less than 190 bps but greater than 110 bps, less than 185 bps but greater than 110 bps, less than 180 bps but greater than 110 bps, less than 175 bps but greater than 110 bps, less than 170 bps but greater than 110 bps, less than 165 bps but greater than 110 bps, less than 160 bps but greater than 110 bps, less than 155 bps but greater than 110 bps, less than 150 bps but greater than 110 bps, less than 145 bps but greater than 110 bps, or less than 140 bps but greater than 110 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 120 bps, less than 400 bps but greater than 120 bps, less than 350 bps but greater than 120 bps, less than 300 bps but greater than 120 bps, less than 275 bps but greater than 120 bps, less than 250 bps but greater than 120 bps, less than 225 bps but greater than 120 bps, less than 200 bps but greater than 120 bps, less than 195 bps but greater than 120 bps, less than 190 bps but greater than 120 bps, less than 185 bps but greater than 120 bps, less than 180 bps but greater than 120 bps, less than 175 bps but greater than 120 bps, less than 170 bps but greater than 120 bps, less than 165 bps but greater than 120 bps, less than 160 bps but greater than 120 bps, less than 155 bps but greater than 120 bps, less than 150 bps but greater than 120 bps, less than 145 bps but greater than 120 bps, or less than 140 bps but greater than 120 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 130 bps, less than 400 bps but greater than 130 bps, less than 350 bps but greater than 130 bps, less than 300 bps but greater than 130 bps, less than 275 bps but greater than 130 bps, less than 250 bps but greater than 130 bps, less than 225 bps but greater than 130 bps, less than 200 bps but greater than 130 bps, less than 195 bps but greater than 130 bps, less than 190 bps but greater than 130 bps, less than 185 bps but greater than 130 bps, less than 180 bps but greater than 130 bps, less than 175 bps but greater than 130 bps, less than 170 bps but greater than 130 bps, less than 165 bps but greater than 130 bps, less than 160 bps but greater than 130 bps, less than 155 bps but greater than 130 bps, less than 150 bps but greater than 130 bps, less than 145 bps but greater than 130 bps, or less than 140 bps but greater than 130 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 140 bps, less than 400 bps but greater than 140 bps, less than 350 bps but greater than 140 bps, less than 300 bps but greater than 140 bps, less than 275 bps but greater than 140 bps, less than 250 bps but greater than 140 bps, less than 225 bps but greater than 140 bps, less than 200 bps but greater than 140 bps, less than 195 bps but greater than 140 bps, less than 190 bps but greater than 140 bps, less than 185 bps but greater than 140 bps, less than 180 bps but greater than 140 bps, less than 175 bps but greater than 140 bps, less than 170 bps but greater than 140 bps, less than 165 bps but greater than 140 bps, less than 160 bps but greater than 140 bps, less than 155 bps but greater than 140 bps, or less than 150 bps but greater than 140 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 150 bps, less than 400 bps but greater than 150 bps, less than 350 bps but greater than 150 bps, less than 300 bps but greater than 150 bps, less than 275 bps but greater than 150 bps, less than 250 bps but greater than 150 bps, less than 225 bps but greater than 150 bps, less than 200 bps but greater than 150 bps, less than 195 bps but greater than 150 bps, less than 190 bps but greater than 150 bps, less than 185 bps but greater than 150 bps, less than 180 bps but greater than 150 bps, less than 175 bps but greater than 150 bps, less than 170 bps but greater than 150 bps, less than 165 bps but greater than 150 bps, or less than 160 bps but greater than 150 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 160 bps, less than 400 bps but greater than 160 bps, less than 350 bps but greater than 160 bps, less than 300 bps but greater than 160 bps, less than 275 bps but greater than 160 bps, less than 250 bps but greater than 160 bps, less than 225 bps but greater than 160 bps, less than 200 bps but greater than 160 bps, less than 195 bps but greater than 160 bps, less than 190 bps but greater than 160 bps, less than 185 bps but greater than 160 bps, less than 180 bps but greater than 160 bps, less than 175 bps but greater than 160 bps, or less than 170 bps but greater than 160 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 170 bps, less than 400 bps but greater than 170 bps, less than 350 bps but greater than 170 bps, less than 300 bps but greater than 170 bps, less than 275 bps but greater than 170 bps, less than 250 bps but greater than 170 bps, less than 225 bps but greater than 170 bps, less than 200 bps but greater than 170 bps, less than 195 bps but greater than 170 bps, less than 190 bps but greater than 170 bps, less than 185 bps but greater than 170 bps, or less than 180 bps but greater than 170 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 180 bps, less than 400 bps but greater than 180 bps, less than 350 bps but greater than 180 bps, less than 300 bps but greater than 180 bps, less than 275 bps but greater than 180 bps, less than 250 bps but greater than 180 bps, less than 225 bps but greater than 180 bps, less than 200 bps but greater than 180 bps, less than 195 bps but greater than 180 bps, or less than 190 bps but greater than 180 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 190 bps, less than 400 bps but greater than 190 bps, less than 350 bps but greater than 190 bps, less than 300 bps but greater than 190 bps, less than 275 bps but greater than 190 bps, less than 250 bps but greater than 190 bps, less than 225 bps but greater than 190 bps, or less than 200 bps but greater than 190 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 200 bps, less than 400 bps but greater than 200 bps, less than 350 bps but greater than 200 bps, less than 300 bps but greater than 200 bps, less than 275 bps but greater than 200 bps, less than 250 bps but greater than 200 bps, or less than 225 bps but greater than 200 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 210 bps, less than 400 bps but greater than 210 bps, less than 350 bps but greater than 210 bps, less than 300 bps but greater than 210 bps, less than 275 bps but greater than 210 bps, less than 250 bps but greater than 210 bps, or less than 225 bps but greater than 210 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 220 bps, less than 400 bps but greater than 220 bps, less than 350 bps but greater than 220 bps, less than 300 bps but greater than 220 bps, less than 275 bps but greater than 220 bps, or less than 250 bps but greater than 220 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 230 bps, less than 400 bps but greater than 230 bps, less than 350 bps but greater than 230 bps, less than 300 bps but greater than 230 bps, less than 275 bps but greater than 230 bps, or less than 250 bps but greater than 230 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 240 bps, less than 400 bps but greater than 240 bps, less than 350 bps but greater than 240 bps, less than 300 bps but greater than 240 bps, less than 275 bps but greater than 240 bps, or less than 250 bps but greater than 240 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 250 bps, less than 400 bps but greater than 250 bps, less than 350 bps but greater than 250 bps, less than 300 bps but greater than 250 bps, or less than 275 bps but greater than 250 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 260 bps, less than 400 bps but greater than 260 bps, less than 350 bps but greater than 260 bps, less than 300 bps but greater than 260 bps, or less than 275 bps but greater than 260 bps. In some embodiments of any one of the compositions or methods provided herein, the DNA thread is less than 450 bps but greater than 270 bps, less than 400 bps but greater than 270 bps, less than 350 bps but greater than 270 bps, less than 300 bps but greater than 270 bps, less than 290 bps but greater than 270 bps, or less than 280 bps but greater than 270 bps. It should be appreciated that the DNA thread can be any size that is compatible with the tRNA to be delivered and / or the desired effects, such as those provided herein. Nucleotide sequences encoding several hundred human tRNAs are known and generally available to those of skill in the art through sources such as GenBank. The structure of tRNAs is highly conserved, and tRNAs can be functional across species. Thus, bacterial or other eukaryotic tRNA sequences are also potential sources for the tRNAs of the present disclosure. The determination of whether a particular tRNA is functional as desired, such as in a desired mammalian cell, can be ascertained as described herein or through other experimentation that will be apparent to one of ordinary skill in the art with the benefit of the teachings provided herein. In some embodiments, a tRNA is 70-90 nt (e.g., 70-90, 70-85, 70- 80, 70-75, 75-90, 75-85, 75-80, 80-90, 80-85, or 85-90) in length. In some embodiments, the tRNA sequences may be any of the sequences provided in PCT / US2018 / 059065, WO2019 / 090154, WO2019 / 090169, and Lueck et al., Nature Communications 10, 822, 2019, the sequences of which are incorporated herein by reference. In an embodiment of any one of the compositions or methods provided herein, the DNA thread comprises a nucleotide sequence encoding an engineered tRNA (e.g., a tRNA modified from a naturally occurring tRNA in its structure and / or function). tRNAs have the potential to correct defects in damaged or mutated mRNA molecules by delivering a correct amino acid where an incorrect amino acid may normally be delivered. tRNAs may also have the potential to reduce the amount of protein in a cell by delivering an incorrect amino acid wherein a correct amino acid may normally be delivered, thereby rendering the consequent amino acid defective and unable to fold and / or susceptible to protein degradation. In an embodiment of any one of the compositions or methods provided herein, the DNA thread comprises a nucleotide sequence encoding a tRNA (e.g., engineered tRNA with an engineered anti-codon arm) that can read through one or more premature termination codon (PTC). As used herein, “premature termination codon” or PTC, refers to single nucleotide mutations that convert a canonical triplet nucleotide codon into one of three stop codons, e.g., TAG, TGA, or TAA. While there are only 3 stop codons currently known in the art, there are 23 different nucleotide substitutions that can lead to a stop codon. For example, the UGA stop codon can be derived from codons for arginine (CGA, AGA), glycine (GGA), leucine (UUA), serine (UCA), cysteine (UGU, UGC) and tryptophan (UGG). The presence of the stop codon, or a termination codon, signals a halt to protein synthesis (i.e., the termination of the translation process of the current protein). PTCs can cause truncation of a protein, thereby causing abnormalities and diseases. In an embodiment, any one of the DNA thread provided herein may comprise a nucleotide sequence encoding any one of the tRNAs of Table 1. Table 1 In an embodiment of any one of the compositions or methods provided herein, the DNA thread described herein further comprises a promoter or a leader sequence. The promoter characteristically has a specific nucleotide sequence necessary to initiate transcription. In some embodiments, the promoter or leader sequence is operably linked to the nucleotide sequence encoding the tRNA. The promoter characteristically has a specific nucleotide sequence necessary to initiate transcription. In some embodiments, a promoter is capable of directing expression of a particular nucleotide sequence in an appropriate cell. In some embodiments, the expression cassette as provided herein may be useful for heterologous expression (e.g., driven by the promoter). In some embodiments, the promoter is a regulatable promoter. In some embodiments, the promoter is a constitutive promoter. The promoter to drive expression of the RNA of interest can be any desired promoter, selected by known considerations, such as the level of expression of a nucleic acid functionally linked to the promoter and the cell type in which the vector is to be used. Promoters can be an exogenous or an endogenous promoter. In an embodiment of any one of the compositions or methods provided herein, promoters (or leader sequences) may be between (35-105 bp in size). The promoters may be any known promoters, including native tRNA leader sequences, which sequences may be ~ 50-60 bp in size. In an embodiment of any one of the compositions or methods provided herein, the promoter (or leader sequences may be reduced-sequence or re-configured promoters. In an embodiment of any one of the compositions or methods provided herein, the promoter is any one of the promoters provided herein. Example promoter or leader sequences that may be comprised in any one of the DNA threads provided herein include, but are not limited to, any one of the sequences in Table 2. Table 2 AAAGAATAGGAATTGCCAAATGAAACTGTTGAGAAGAGAAACATTACACATATCA In an embodiment of any one of the compositions or methods provided herein, the DNA thread may further include additional sequences. In some embodiments, the DNA thread may further comprise a transcription terminator, e.g., located 3’ to the nucleotide sequence encoding the tRNA. In some embodiments of any one of the compositions or methods provided herein, the DNA thread may further comprise a tRNA tail or trailer sequence, e.g., located 3’ to the nucleotide sequence encoding the tRNA. Such sequences may be between 2-20 bp in length. They may include natural sequences or engineered variants with 3-10 consecutive “T” residues. In an embodiment, any one of the DNA threads provided herein may comprise any one of the sequences of Table 3. Table 3 In some embodiments of any one of the compositions or methods provided herein, the DNA thread may further comprise a DNA targeting sequence (DTS). DTS are sequences of DNA recognized by nuclear transcription factors found in the cytosol. DNA containing DTS can be bound by transcription factors in the cytosol and shuttled into the nucleus in an importin-mediated process. The location of a DTS within a DNA thread may vary. For example, the DTS may be located 5’ or 3’ of the nucleotide sequence encoding a tRNA. Non-limiting examples of DNA targeting sequences include any one of the DTS sequences provided herein, including the SV40 enhancer, HRE, etc. Minimal random or restriction-enzyme site spacer sequences of 0 to 80 bp may also be included in any one of the DNA threads provided herein. Example restriction enzyme sequences that could be introduced in part, in whole, and / or as part of a joining series include, but are not limited to, those of Table 4. In an embodiment of any one of the compositions or methods provided herein, any one of the DNA threads provided herein may comprise any one of the sequences of Table 4. Table 4 In an embodiment, the DNA thread comprises any one of the sequences of Table 5. Table 5 DNA thread with two open ends While it has been generally viewed that “open” DNA molecules with exposed DNA ends can be attacked by enzymes, such as exonucleases, and as a result can have reduced stability and longevity, it has been surprisingly found that open ended DNA threads can be used in tRNA therapeutics as provided herein. In an embodiment of any one of the compositions or methods provided herein, the DNA thread has at least one open end. In some embodiments of any one of the compositions or methods provided herein, the DNA thread can terminate with at least one “sticky end”, a “blunt end”, or a “frayed end.” In some embodiments of any one of the compositions or methods provided herein, at least one end of a DNA thread comprises a sticky end, i.e., where one complementary strand of the linear open-end DNA construct can be longer than the other by a least a few nucleotides (i.e., one strand is longer than the complementary strand). In some embodiments of any one of the compositions or methods provided herein, at least one end of a DNA thread comprises a blunt, i.e., where both strands terminate in a base pair. In some embodiments of any one of the compositions or methods provided herein, at least one end of a DNA thread comprises a frayed end, i.e., a region near the end of an open-end DNA construct containing non-complementary sequences that may fail to appropriately bond. In an embodiment of any one of the compositions or methods provided herein, the DNA thread has two open ends, e.g., linear open-ended DNA construct, and each end may be independently one of the foregoing. In some embodiments of any one of the compositions or methods provided herein, manufacture of linear open-end DNA constructs can be completely synthetic, enabling rapid design and ease of production. Linear open-end DNAconstructs can be made using methods known in the art. Production of linear open-end DNA constructs has been described in M. H. Caruthers, Methods in Enzymology 154, 287-313, 1987; WO 2005 / 051970, WO 2008 / 022789, WO 2010 / 094772; WO 2013 / 112923, which production steps are hereby incorporated by reference. The preparation can, for example, follow a two-step procedure: (i) production of a 'parental plasmid' (bacterial plasmid with eukaryotic inserts) containing ; and (ii) induction of a site-specific enzymatic excision and recovery of the desired sequence by gel electrophoresis. As a nonlimiting example, a linear open-end DNA construct may be produced as follows. A circular DNA plasmid, which can comprise the polynucleotide coding sequence along with regulatory elements for its expression and at least one restriction enzyme cleavage site, is produced. In some embodiments, the DNA plasmid is processed with restriction enzymes to convert a circular plasmid DNA into a linear open-end DNA construct in a single-step enzyme reaction. In some embodiments, the circular DNA plasmid can contain two or more restriction enzyme cleavage sites, which result in multiple linear open-end DNA constructs after processing with restriction enzymes. In some embodiments, a DNA plasmid contains at least one recognition site for and is processed with an EcoRI (pronounced "eco R one") restriction enzyme, resulting in a sticky end construct termination. In some embodiments, a DNA plasmid contains at least one recognition site for and is processed with a Smal restriction enzyme, resulting in a blunt end construct termination. DNA thread with one closed end and one open end In an embodiment of any one of the compositions or methods provided herein, the DNA thread has one closed end and one open end, e.g., a hairpin loop DNA construct. In some embodiments of any one of the compositions or methods provided herein, the DNA thread has an open 5’ end and a closed 3’ end. In some embodiments of any one of the compositions or methods provided herein, the DNA thread has a closed 5’ end and an open 3’ end. A hairpin loop DNA construct refers to a linear double-stranded DNA molecule comprising one covalently closed end joined by a hairpin loop and one open end. In some embodiments of any one of the compositions or methods provided herein, a hairpin loop joins one of the 5’ and 3’ ends of paired complementary nucleotide sequences. For example, denatured hairpin loop DNA constructs with one end connected by a hairpins loop would form a singular stranded DNA molecule comprising adjacent complementary nucleotide strands. A hairpin loop can be an essential unit of the structure of single stranded RNA or DNA. A hairpin loop can consist of a stem, double helix, and a loop typically comprising 3-8 nucleotides which links complementary nucleotide sequences of the stem (Figure 3; middle panel). In some embodiments of any one of the compositions or methods provided herein, the hairpin loop can comprise greater than 8 nucleotides. In some embodiments of any one of the compositions or methods provided herein, the open end of a hairpin loop DNA construct can be a sticky end, a blunt end, or a frayed end. In some aspects, manufacture of hairpin loop DNA constructs can be completely synthetic, enabling rapid design and ease of production. Hairpin loop DNA constructs can be made using methods known in the art. Production of hairpin loop DNA constructs has been described at least in US5514546A, WO 2007 / 018601, WO 2011 / 159256, and WO 2014 / 176599, which production steps are hereby incorporated by reference. As a nonlimiting example, a hairpin loop DNA construct may be produced as follows. A linear single-stranded sequence which can comprise complementary sequences of a desired nucleotide sequence along with regulatory elements for its expression separated by nucleotides which will comprise the hairpin loop is produced. In some embodiments of any one of the compositions or methods provided herein, the linear single-stranded nucleotide sequence is capable of complementary binding between the complementary sequences and the formation of a hairpin. For example, the stem portion of the hairpin is a pseudo-double stranded nucleotide comprising a hairpin connecting the base paired sequences. In some embodiments of any one of the compositions or methods provided herein, the hairpin loop DNA construct can comprise restriction enzyme recognition sites which allow for the generation selective open ends at the DNA construct. For example, the hairpin loop can contain sequences of a restriction enzyme recognition site. In some embodiments of any one of the compositions or methods provided herein, complementary binding and formation of the hairpin loop can occur, and the DNA thread can be further processed using restriction enzymes (i.e., EcoRI or Smal) to generate a blunt end or a sticky end opposite the end of the hairpin loop. In some embodiments of any one of the compositions or methods provided herein, the nucleotides located at the 5’ and 3’ ends of linear single-stranded nucleotide sequence are not complementary, and upon hairpin loop formation, may not bind, and a frayed end on the opposite end of the hairpin loop occurs. DNA thread with two closed ends In an embodiment of any one of the compositions or methods provided herein, the DNA thread has two closed ends, e.g., a linear closed-end DNA construct. A linear closed-end DNA construct refers to a closed linear double-stranded DNA molecule comprising covalently closed ends, e.g., ends joined by hairpin loops. In some embodiments of any one of the compositions or methods provided herein, the hairpin loops join the 5’ and 3’ ends of paired complementary nucleotide sequences (e.g., shown in Figure 3, left panel). For example, denatured linear closed- end DNA constructs with ends connected by hairpins loops could form a circular single stranded DNA molecule comprising adjacent complementary nucleotide strands. In some embodiments of any one of the compositions or methods provided herein, the nucleotides comprising the hairpin loop of the linear closed-end DNA construct are complementary; however, the nucleotides are unable to form complementary because of conformational stress imparted from the hairpin loop onto the DNA strand. The stability of the loop influences the formation of the hairpin loop structure. Hairpin loops fewer than three bases long are sterically impossible and do not form. In some embodiments of any one of the compositions or methods provided herein, the optimal loop length can be about 4-8 bases long, but preferred conformations are likely subject to variations in, for example, DNA maintenance and storage conditions, and the nucleotide sequences surrounding the hairpin. In some aspects, manufacture of linear closed-end DNA constructs can be completely synthetic, enabling rapid design and ease of production. Linear closed-end DNA constructs can be made using methods known in the art. A cell-free production of linear closed-end DNA constructs has been described in WO 2010 / 086626, WO 2012 / 017210, and WO 2021 / 252354, which production steps are hereby incorporated by reference. The preparation can, for example, follow a two-step procedure: (i) production of a 'parental plasmid' (bacterial plasmid with eukaryotic inserts) or linear DNA construct containing a protelomerase resolution site; and (ii) induction of a protelomerase enzymatic reaction and recovery of the desired sequence by gel electrophoresis. As a nonlimiting example, a linear closed-end DNA construct may be produced as follows. A circular DNA plasmid, which can comprise the polynucleotide coding sequence along with regulatory elements for its expression and at least one protelomerase resolution site (telRL), is produced. In some embodiments, the circular DNA plasmid is processed with protelomerase TelN, acting on a telRL site, to convert a circular plasmid DNA into linear covalently closed DNA construct in a single-step enzyme reaction. In some embodiments, the circular DNA plasmid can contain two or more telRL sites, which result in multiple linear closed-end DNA constructs after processing with protelomerase. In some embodiments, a linear closed-end DNA construct may be produced from linear open-end DNA constructs comprising at least two telRL sites. Processing a linear DNA construct comprising at least two telRL sites with protelomerase can result in at least one linear closed-end DNA construct. In some embodiments of any one of the compositions or methods provided herein, the DNA thread with two closed ends is a supercoiled helix. DNA supercoiling refers to the amount of twist in a particular DNA strand. Supercoiled DNA can be positively supercoiled DNA or negatively supercoiled DNA. As used herein, “supercoiled DNA” refers to a DNA molecule, or fragment of a DNA molecule, wherein one or both DNA strands comprise increased twisting compared to the amount of twisting in a reference state known as "relaxed B-form" DNA. In a “relaxed” double-helical segment of DNA, the two strands twist around the helical axis once every 10.4–10.5 base pairs of sequence. A given DNA strand may be "positively supercoiled" or "negatively supercoiled" (i.e., more or less tightly wound). Supercoiling creates twist strain in the DNA strand. The amount of a strand’s supercoiling affects a number of biological processes, such as compacting DNA and regulating access to the genetic code (which strongly affects DNA metabolism and possibly gene expression). Certain enzymes (e.g., topoisomerases) are capable of increasing or decreasing the amount of twisting (e.g., supercoiling) in a DNA strand in order to facilitate functions such as DNA replication and transcription. In some aspects of the present disclosure, compositions comprising DNA threads are provided. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, a pharmaceutical composition may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, solubilizing or emulsifying agents, and salts of the type that are well-known in the art. Specific non-limiting examples of the carriers and / or diluents that are useful in the pharmaceutical formulations of the present disclosure include water and physiologically acceptable buffered saline solutions such as phosphate buffered saline solutions pH 6.0-9.0 and water. Any of the compositions provided herein can be placed in contact with, administered to or introduced into a cell with genetic transfer methods, such as transfection. The DNA threads or compositions comprising such DNA threads provided herein can be contacted (e.g., directly) with cells (e.g., cells in vitro or in a subject) or delivered or administered to a subject within a particle, such as a nanoparticle. A particle, such as a nanoparticle, can be, but is not limited to, lipid-based nanoparticles (also referred to herein as lipid nanoparticles, i.e., nanoparticles where the majority of the material that makes up their structure are lipids) and / or particles with a combination of nanomaterials. The particles may be a variety of different shapes, including but not limited to spheroidal, cuboidal, pyramidal, oblong, cylindrical, toroidal, and the like. In some embodiments of any one of the compositions or methods provided herein, particles, such as nanoparticles, may comprise one or more lipids. In some embodiments of any one of the compositions or methods provided herein, particles, such as nanoparticles, may comprise liposomes. In some embodiments of any one of the compositions or methods provided herein, particles, such as nanoparticles, may comprise a lipid bilayer. In some embodiments of any one of the compositions or methods provided herein, particles, such as nanoparticles, may comprise a lipid monolayer. In some embodiments of any one of the compositions or methods provided herein, particles, such as nanoparticles, may comprise a micelle. The nucleic acid molecules, the DNA threads or compositions provided herein can be contacted with cells or delivered or administered to a subject with an extracellular vesicle or exosome. Generally, exosomes are nano-sized extracellular vesicles (EVs) (30–150 nm in diameter) which can be formed and released by many mammalian cells. The EVs or exosomes can be loaded with an agent of interest, for example by pre-treatment of cells with the agent and then isolation of loaded EVs or exosomes. EVs or exosomes can be derived from human embryonic kidney cells, bone marrow stem cells, immature dendritic cells, red blood cells as well as from milk. EVs or exosomes can be isolated and purified with a number of different techniques. Such methods include, but are not limited to ultracentrifugation, ultrafiltration, size exclusion chromatography (SEC), precipitation with polymers, and separation by affinity-based methods, such as immunomagnetic-based isolation. Electroporation may also be used for delivery or administration. In some embodiments of any one of the compositions or methods provided herein, the DNA threads or compositions provided herein can be used for administration to a subject, such as for treatment of the subject. In some embodiments of any one of the compositions or methods provided herein, the DNA threads can be administered ex vivo to cells harvested from the subject, the cells are then administered to the subject (e.g., for therapy). In some embodiments of any one of the compositions or methods provided herein, the DNA threads or compositions provided herein can be used for restoring protein translation in a subject, for altering a resulting protein, etc. The DNAthreads or compositions provided herein can be used to correct for a nonsense or missense mutation. The DNA threads or compositions provided herein can be used to replace a stop codon or other codon with an alternate amino acid in a protein or portion thereof. The present disclosure provides methods of treating a subject in need thereof, such as one with a disease or disorder. In some embodiments, the methods comprise administering to a subject the DNA threads or compositions provided herein. In some embodiments of any one of the compositions or methods provided herein, the disease or disorder may include a genetic disease or disorder or a hyperproliferative disease or disorder. In some embodiments of any one of the compositions or methods provided herein, the disease or disorder may be cancer. The tRNAs encoded by the DNA threads or compositions provided herein can also be used to disrupt protein expression and / or function, preferably the protein expression and / or function of a protein encoded by an oncogene or tumor suppressor gene. The DNA threads or compositions provided herein can also be used where cell survival or mobility would be a benefit. The DNA threads or compositions provided herein can also be used to restore protein expression and / or function. In some embodiments of any one of the compositions or methods provided herein, the disease or disorder may be any disease or disorder (e.g., disease or disorder caused by protein dysfunction) that can benefit from a tRNA treatment. The DNA threads or compositions provided herein as described herein can be delivered to a cell in vivo or in vitro. Administration to the cell can be accomplished by any means, including simply contacting the cell. The contact with the cells can be for any desired length of time. The cells can include any desired cell in humans as well as other large (non- rodent) mammals, such as primates, horse, sheep, goat, pig, and dog. Any one of the subjects provided herein can be a human or other mammal. The term "mammal" includes, but is not limited to, humans, mice, rats, guinea pigs, monkeys, dogs, cats, horses, cows, pigs, and sheep. In some embodiments, administration can be systemic. In some embodiments, administration can be local. In some embodiments, administration can be direct delivery to the selected organ, oral, inhalation, intraocular, intravenous including facial vein injection and retroorbital injection, intracerebroventricular (ICV), intracisterna magna (ICM) injection, intramuscular, intrathecal, intracranial, subcutaneous, intradermal, intratumoral, and other parental routes of administration. Routes of administration may be combined, if desired. In some embodiments, the DNA threads or compositions provided herein can be administered via any route that is appropriate for the present disclosure. Vehicles including water, aqueous saline, artificial CSF, or other known substances can be employed. To prepare a formulation, the purified composition can be isolated. The composition may then be adjusted to an appropriate concentration and packaged for use. As used herein, the terms "treat" and "treatment" refer to both therapeutic treatment and measures that can alleviate symptoms or provide some benefit to a subject, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the growth, development or spread of cancer. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. In some embodiments, "treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. In some embodiments, "treatment" can also mean delaying progression of disease as compared to the progression of disease if not receiving treatment. Those in need of treatment include those already with the condition, disease or disorder. As is apparent to those skilled in the art in view of the teachings of this specification, an effective amount of the DNA threads or compositions provided herein provided may be empirically determined. Administration can be effected in one dose, continuously or intermittently, throughout the course of treatment. Methods of determining the most effective means and dosages of administration may vary with the composition of the therapy, target cells, and the subject being treated, etc. Single and multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. The phrase "therapeutically effective amount" means an amount of a DNA thread provided herein that (i) treats the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and / or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth and / or kill existing cancer cells, it may be cytostatic and / or cytotoxic. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease progression (TTP) and / or determining the response rate (RR). The phrase "reduced effective dose" refers a reduced amount (e.g., reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or more) of a DNA thread provided herein relative to related nucleic acid preparation and delivery systems for the treatment of the particular disease, condition, or disorder, such that the reduced effective dose attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, and prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein. Furthermore, the “reduced effective dose” refers to the improved potential relative to many forms of encoding DNA (e.g., plasmids). Comparisons can be made with such other forms in a test subject to show DNA threads and compositions thereof that have effectiveness at reduced doses. The DNA threads or compositions provided herein can have enhanced nuclear entry. “Enhanced nuclear entry” refers to a DNA thread or composition thereof that enters the nucleus in increased amounts as compared to another composition that encodes a tRNA, such as the same tRNA. The other composition may encode all of the same elements as the DNA thread but be in a different form for delivery, such as a plasmid, such as a nanoplasmid. Tests in vitro or in vivo, such as in a test subject, can be performed to demonstrate that a DNA thread or composition thereof has enhanced nuclear entry as compared to another composition. Generally, such tests allow one to determine that greater amounts of nuclear entry is due to the format of the encoded element or elements that is contacted with cells or delivered to cells of a subject, such as a test subject. The DNA threads or compositions provided herein can have no or less immunogenicity. “Less immunogenicity” refers to a DNA thread or composition thereof that stimulates one or more undesirable immune responses at a reduced level as compared to another composition that encodes a tRNA, such as the same tRNA. The other composition may encode all of the same elements as the DNA thread but be in a different form for delivery, such as a plasmid, such as a nanoplasmid. Tests in vitro or in vivo, such as in a test subject, can be performed to demonstrate that a DNA thread or composition thereof stimulates one or more immune responses at a reduced level as compared to another composition. Such tests include, but are not limited to, tests that assess cGAS activation, cytokine release, etc. The cytokines tested may be any one or more or combination of those provided herein, including in the Examples and Figures. Generally, such tests allow one to determine that reduced levels of immune responses, or the aforementioned indicators of immune responses, is due to the format of the encoded element or elements that is contacted with cells or delivered to cells of a subject, such as a test subject. “No immunogenicity” refers to a DNA thread or composition thereof that a person of ordinary skill in the art would deem as not resulting in or not resulting in in a substantial and / or clinically meaningful way one or more undesired immune responses. Such immune responses can be tested in vitro or in vivo, such as in a test subject, according to the foregoing. Such tests include, but are not limited to, tests that assess cGAS activation, cytokine release, etc. The cytokines tested may be any one or more or combination of those provided herein, including in the Examples and Figures. Other tests for the foregoing would be apparent to one of ordinary skill in the art. The DNA threads or compositions provided herein can be administered so as to result in a reduction in at least one symptom associated with a disease or disorder, such as a genetic disease or disorder or a hyperproliferative disease or disorder (e.g., cancer). The amount administered will vary depending on various factors including, but not limited to, the composition chosen, the particular disease, the weight, the physical condition, and the age of the mammal. Such factors can be readily determined by the clinician employing animal models or other test systems that are known to the art. As used herein, a “genetic disease or disorder” is a disease or disorder that is caused by mutations that are inherited or that arise within a subject’s genetic code or that predisposes a subject to a disease or disorder. Any one of the compositions or methods provided herein can be for treating or preventing a genetic disease or disorder. As used herein, “hyperproliferative disease or disorder” refers to any disease or disorder where there is an abnormally high rate of proliferation of cells by rapid division, substantial over proliferation, etc., such as cancer. Certain embodiments of the present disclosure provide a method of treating a disease or disorder, such as a hyperproliferative disease or disorder in a subject. Certain embodiments of the present disclosure provide a use of the DNA threads or compositions to prepare a medicament useful for treating a disease or disorder, such the foregoing, in a subject. In certain embodiments, the therapy has potential use for the treatment / management of the disease or disorder, such as the foregoing, including tumors, cancers, and neoplastic tissue, along with non-neoplastic or non- malignant hyperproliferative disorders. In certain embodiments, the hyperproliferative disease or disorder is cancer. In certain embodiments, the subject is a mammal. In certain embodiments, the subject is human. Administration may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic, and other factors known to skilled practitioners. The administration may be essentially continuous over a preselected period of time or may be in a series of spaced doses. The DNA threads or compositions provided herein may be formulated for administration and may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative. The active ingredients may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Alternatively, the active ingredients may be in a suitable vehicle, e.g., sterile, pyrogen-free water, before use. It will be appreciated that the unit content of active ingredient or ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount for treating the particular indication or disease since the necessary effective amount can be reached by administration of a plurality of dosage units. Moreover, the effective amount may be achieved using less than the dose in the dosage form, either individually, or in a series of administrations. EXAMPLES Example 1 - Premature termination codon (PTC) suppression activity and immune stimulating properties of small linear DNAs (slDNAs) Short linear double stranded DNAs were used as models to evaluate the premature termination codon (PTC) suppression activity and immune stimulating properties of DNA threads. Multiple short linear dsDNA (slDNAs) were designed to test the activity of different cassette features (Table 6). First, PTC suppression activity was evaluated by transfecting amplified open-ended slDNAs into HEK293T cells expressing a nanoluciferase containing a TGA PTC (Figure 4A). Activity was read out as nanoluciferase activity from proteins corrected by ArgTGA tRNA expressed from open-ended slDNAs constructs (Figure 4B). Many open ended slDNA designs showed in vitro activity up to ~10-20% as compared to a positive control containing an ArgTGA-expressing nanoplasmid. A closed end slDNA construct was also tested for PTC activity (Figure 8A). As with the open ended slDNA constructs, the closed ended slDNA construct showed PTC suppression across a range of concentrations (0.02 μg / mL – 2 μg / mL; Figure 8B). The same open ended slDNA constructs were then tested for cGAS activation in HeLa cells (Figure 5A). Briefly, each slDNA construct was transfected into HeLa cells using lipofectamine. A positive control comprising an ArgTGA-expressing nanoplasmid was also transfected into HeLa cells. cGas activity was read out from cellular cGAMP concentration by cGAMP ELISA. Many constructs showed very low cGAS activation and all constructs induced less cGAS activation than the positive control (Figure 5B). Additionally, the inclusion of phosphorothioate modifications in an slDNA construct was found to increase cGAS activation. A construct demonstrating high in vitro activity and low cGAS activation was selected, and an immunogenicity study was conducted to compare the induction of cytokines from PBMC relative to an ArgTGA-expressing nanoplasmid. First, the slDNA construct and the ArgTGA- expressing nanoplasmid were encapsulated in lipid nanoparticles and incubated with human PBMCs (Figure 6A). Cytokine levels read out on MSD showed that the dsDNA construct showed low or no immunogenicity compared to the nanoplasmid DNA in human PBMCs (Figures 6B- 6E). Next, the constructs were evaluated in C57BL / 6 wild-type mice to observe in vivo cytokine induction (Figure 7A). Briefly, C57BL / 6 wild-type mice were injected intravenously with a lipid nanoparticle comprising either the slDNA construct or the ArgTGA-expressing nanoplasmid. Mouse sera was collected 4 hours post injection for cytokine analysis. As in the in vitro study, the slDNA construct induced lower levels of cytokines than the ArgTGA-expressing nanoplasmid (Figures 7B-7E). Next, the PTC suppression activity of a GlnTAA tRNA expressed from an open ended slDNA was evaluated by transfecting the slDNA into mCherry-STOP(TAA)-EGFP cells, which only express mCherry and eGFP if the TAA stop codon is suppressed by the suppressor tRNA (Figure 9A). Compared to a positive control of a cell line stably expressing mCherry-EGFP tandem protein with no stop and no treatment, two batches of treatment with the slDNA showed expression of EGFP, suggesting readthrough of the TAA stop codon at the end of mCherry (Figures 9B-9C). Finally, the PTC suppression activity of the GlnTAA tRNA was evaluated in vivo a mouse model of muscular dystrophy (mdx mouse). Mdx mice have a GlnTAA PTC in their dystrophin gene, resulting in premature termination and degradation of the dystrophin protein, leading to the disease phenotype. Briefly, mdx mice were administered an open sended GlnTAA tRNA by intramuscular injection and electroporation to the tibialis anterior muscle (Figure 10A). Mice were evaluated 7 days post injection. Gel electrophoresis analysis showed restoration of full length dystrophin after GlnTAA tRNA treatment across multiple biological replicates (Figures 10B-10C). Approximately 10% of the dystrophin protein was restored (Figure 10D), indicating activity of the GlnTAA suppressor tRNA in vivo after expression from a slDNA. Table 6 Example 2 - Premature termination codon (PTC) rescue activity of small linear DNAs (slDNAs) Short linear double stranded DNAs were used as models to evaluate the premature termination codon (PTC) rescue activity of DNA threads of varying lengths. Previously, it was found that certain shorter DNA threads were less efficacious than a plasmid-based delivery format. Surprisingly, PTC rescue of even the shortest DNA threads tested can approach that of longer DNA threads and even a nanoplasmid control. Multiple short linear dsDNA (slDNAs) were designed to test PTC rescue activity. PTC suppression activity was evaluated by transfecting 5’ extended fragments slDNAs with various lengths into HEK293T cells expressing a nanoluciferase containing a PTC (Figure 12). Activity was read out as nanoluciferase activity from proteins corrected by tRNA expressed from the slDNAs constructs. Similarly, rescue activity was evaluated with 3’ extended fragments slDNAs with various lengths (Figure 13) as well as for both-end extended fragments slDNAs with various lengths (Figure 14). PTC rescue activity is also summarized in Figure 15. Of note are the below listed sequences with a DNA thread length as provided herein. Although the foregoing specification and examples fully disclose and enable the present invention, they are not intended to limit the scope of the invention, which is defined by the claims appended hereto. All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention. The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention. Embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
CLAIMS What is claimed is:
1. A DNA thread comprising a nucleotide sequence encoding at least one transfer RNA (tRNA), wherein the DNA thread has a size of between 100-475 bps, 100-450 bps, 100-400 bps, 100-375 bps, or 100-350 bps. 2 The DNA thread of claim 1, wherein the DNA thread is less than 300 bps in size. 3 The DNA thread of claim 2, wherein the DNA thread is less than 275 bps in size. 4 The DNA thread of any one of claims 1-3, wherein the tRNA is any one of the tRNAs provided herein, such as an engineered tRNA or anticodon-edited tRNA. 5 The DNA thread of any one of claims 1-4, wherein the sequence encoding the at least one tRNA comprises any one of the sequences encoding a tRNA provided herein, such as in Table 1 or Table 6. 6 The DNA thread of any one of claims 1-5, further comprising a promoter or a leader sequence, optionally, wherein the promoter or the leader sequence is located at the 5’ end of the DNA thread. 7 The DNA thread of claim 6, wherein the promoter or the leader sequence is operably linked to the nucleotide sequence encoding the tRNA. 8 The DNA thread of claim 6 or claim 7, wherein the promoter or the leader sequence comprises any one of the sequences encoding a promoter or leader provided herein, such as in Table 2 or Table 6. 9 The DNA thread of any one of claims 1-8, further comprising a sequence that encodes a tail or a trailer sequence, optionally, wherein the tail or the trailer sequence is located at the 3’ end of the DNA thread. 10 The DNA thread of claim 9, wherein the tail or the trailer sequence comprises any one ofthe sequences encoding a tail or the trailer provided herein, such as in Table 3 or Table 6.
11. The DNA thread of any one of claims 1-10, wherein the nucleic acid further encodes a spacer sequence.
12. The DNA thread of any one of claims 1-11, wherein the nucleic acid further encodes a DNA-targeting sequence (DTS), optionally, wherein the DTS-encoding sequence is 5’ or 3’ of the sequence encoding the tRNA.
13. The DNA thread of any one of claims 1-12, wherein the DTS comprises any one of the sequences encoding a DTS provided herein, such as in Table 6.
14. The DNA thread of any one of claims 1-13, wherein the DNA thread has one open end.
15. The DNA thread of any one of claims 1-13, wherein the DNA thread has two open ends.
16. The DNA thread of any one of claims 1-13, wherein the DNA thread has two closed ends.
17. The DNA thread of any one of claims 1-16, wherein the DNA thread is formulated with a carrier, such as a synthetic carrier.
18. The DNA thread of claim 17, wherein the synthetic carrier comprises a lipid nanoparticle (LNP), a liposome, a polymeric nanoparticle (NP), a polymersome, an exosome, a polymer / lipid based nanocarrier, or a protein-based nanocarrier.
19. A composition comprising the DNA thread of any one of claims 1-18 and a pharmaceutically acceptable carrier.
20. A method of delivering the DNA thread of any one of claims 1-18 or the composition of claim 19 to cells, comprising contacting the cells with the DNA thread.
21. A method of treating a subject in need thereof, comprising administering the DNA thread of any one of claims 1-18 or the composition of claim 19 to the subject in an amount effective to treat the subject.
22. The method of claim 20 or 21, wherein the subject is a human.
